What LDN is
Naltrexone was originally designed to treat opioid and alcohol addiction at doses of 50-100 mg. It blocks opioid receptors.
Low-dose naltrexone (LDN) uses doses of 0.5-4.5 mg — about 1/10 to 1/30 of the addiction dose. At these low doses, the drug works completely differently: instead of blocking opioid receptors, it briefly occupies them, triggering a feedback response that increases the body's natural endorphins and calms microglia (the immune cells in the brain).
Why it's relevant to Long COVID
Long COVID is increasingly understood as a condition of chronic immune activation, including in the brain and nervous system. LDN:
- Reduces microglial inflammation (the brain's inflammation)
- Modulates the immune system (it's not a direct immunosuppressant, but it dampens excessive activation)
- Improves pain perception in conditions like fibromyalgia, which overlaps heavily with LC
- Can improve sleep quality at low doses
LDN has been studied for decades in fibromyalgia, MS, Crohn's disease, and ME/CFS — all conditions where the immune-inflammation-nervous-system triad is dysregulated. Long COVID fits that pattern.
What the research currently shows
- Observational studies of LC patients on LDN report roughly 50-60% reporting meaningful symptom improvement, especially in fatigue, pain, and brain fog.
- Randomized controlled trials are ongoing but not yet published in large cohorts. What we have so far is open-label and small.
- No large safety signals at doses under 5 mg/day. It's one of the most well-tolerated experimental treatments for LC.
Important: this is emerging evidence, not strong evidence. We don't yet have large double-blind trials proving LDN works for Long COVID specifically. What we have is:
- Decades of safety data at low doses
- Good mechanistic reasons to think it might help
- Positive anecdotal and observational reports from LC patients and clinicians
How it's typically prescribed
LDN is not commercially available at the 1.5-4.5 mg dose — it has to be compounded by a specialized pharmacy that makes the capsules or liquid at the correct dose. Your GP can write a prescription for a compounding pharmacy.
Typical starting protocol:
- Week 1: 0.5 mg at bedtime
- Week 2: 1.5 mg at bedtime
- Week 4: 3.0 mg at bedtime
- Week 6+: 4.5 mg (if tolerated and helping)
Starting slow is key. Jumping to 4.5 mg on day 1 often causes vivid dreams, insomnia, and headaches for the first 1-2 weeks. Starting at 0.5 mg and titrating up usually avoids this.
Side effects to know about
Most common (usually first 2 weeks, then resolve):
- Vivid or strange dreams
- Insomnia or sleep disruption
- Headache
- Mild GI upset
Less common but worth knowing:
- Paradoxical fatigue increase (rare)
- Mood changes (usually improvement, rarely worsening)
- Skin reactions (uncommon)
⚠️ Hard contraindications:
- You're taking opioid painkillers — LDN will block them
- You're on opioid replacement therapy (methadone, buprenorphine)
- Pregnant or breastfeeding (not enough safety data)
Who tends to respond
From observational patient-reported data:
- Fibromyalgia-type pain patients often respond well
- Fatigue with post-exertional component sometimes responds
- Brain fog — mixed results
- POTS-primary LC — less likely to be helpful (LDN doesn't target autonomic mechanisms directly)
If you have pain, sleep disruption, and immune-feeling symptoms (feeling "flu-like"), LDN is reasonable to discuss with a knowledgeable doctor. If your main symptom is cardiovascular (POTS, tachycardia), LDN is probably not your first lever.
What we don't know
- How long improvement takes. Some patients report benefits within 2 weeks, others take 3-6 months.
- How long you should stay on it. Some patients stop after 1 year. Others stay indefinitely.
- Why some people respond and others don't. No reliable predictor yet.
Bottom line
LDN is one of the most promising off-label treatments for Long COVID, with a good safety record and reasonable mechanistic backing. But it's experimental — the randomized trials aren't done yet. If you're considering it, find a doctor who knows LDN (functional medicine MDs and some rheumatologists are often familiar) and start low.